| Nivolumab for recurrent squamous-cell carcinoma of the head and neck RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... New England Journal of Medicine 375 (19), 1856-1867, 2016 | 4982 | 2016 |
| Lenvatinib versus placebo in radioiodine-refractory thyroid cancer M Schlumberger, M Tahara, LJ Wirth, B Robinson, MS Brose, R Elisei, ... New England Journal of Medicine 372 (7), 621-630, 2015 | 2103 | 2015 |
| Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer Y Imamura, T Mukohara, Y Shimono, Y Funakoshi, N Chayahara, ... Oncology reports 33 (4), 1837-1843, 2015 | 948 | 2015 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 786 | 2018 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 437 | 2017 |
| Lenvatinib for anaplastic thyroid cancer M Tahara, N Kiyota, T Yamazaki, N Chayahara, K Nakano, L Inagaki, ... Frontiers in oncology 7, 25, 2017 | 195 | 2017 |
| Weekly low‐dose versus three‐weekly high‐dose cisplatin for concurrent chemoradiation in locoregionally advanced non‐nasopharyngeal head and neck cancer: a systematic review … P Szturz, K Wouters, N Kiyota, M Tahara, K Prabhash, V Noronha, ... The oncologist 22 (9), 1056-1066, 2017 | 188 | 2017 |
| Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial N Kiyota, M Tahara, J Mizusawa, T Kodaira, H Fujii, T Yamazaki, H Mitani, ... Journal of Clinical Oncology 40 (18), 1980-1990, 2022 | 140 | 2022 |
| Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer N Kiyota, M Schlumberger, K Muro, Y Ando, S Takahashi, Y Kawai, ... Cancer science 106 (12), 1714-1721, 2015 | 139 | 2015 |
| A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer S Takahashi, N Kiyota, T Yamazaki, N Chayahara, K Nakano, L Inagaki, ... Future Oncology 15 (7), 717-726, 2019 | 137 | 2019 |
| Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma H Kubota, D Miyawaki, N Mukumoto, T Ishihara, M Matsumura, ... Radiation oncology 16, 1-11, 2021 | 136 | 2021 |
| Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks Y Kataoka, T Mukohara, H Tomioka, Y Funakoshi, N Kiyota, Y Fujiwara, ... Investigational new drugs 30, 1352-1360, 2012 | 132 | 2012 |
| Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin H Goto, Y Shimono, Y Funakoshi, Y Imamura, M Toyoda, N Kiyota, ... Oncogene 38 (6), 767-779, 2019 | 120 | 2019 |
| A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of … N Kiyota, Y Hasegawa, S Takahashi, T Yokota, CJ Yen, S Iwae, Y Shimizu, ... Oral oncology 73, 138-146, 2017 | 118 | 2017 |
| International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ‐HN43: phase IV S Singer, CD Amdal, E Hammerlid, IM Tomaszewska, J Castro Silva, ... Head & neck 41 (6), 1725-1737, 2019 | 111 | 2019 |
| Low-dose vs. high-dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer P Szturz, K Wouters, N Kiyota, M Tahara, K Prabhash, V Noronha, ... Frontiers in oncology 9, 86, 2019 | 108 | 2019 |
| Treatment‐emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT) LJ Wirth, M Tahara, B Robinson, S Francis, MS Brose, MA Habra, ... Cancer 124 (11), 2365-2372, 2018 | 102 | 2018 |
| Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell … M Tahara, N Kiyota, T Yokota, Y Hasegawa, K Muro, S Takahashi, T Onoe, ... Annals of Oncology 29 (4), 1004-1009, 2018 | 93 | 2018 |
| CheckMate 141: 1‐year update and subgroup analysis of nivolumab as first‐line therapy in patients with recurrent/metastatic head and neck cancer ML Gillison, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... The oncologist 23 (9), 1079-1082, 2018 | 92 | 2018 |
| Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651 RI Haddad, K Harrington, M Tahara, RL Ferris, M Gillison, J Fayette, ... Journal of Clinical Oncology 41 (12), 2166-2180, 2023 | 89 | 2023 |
